Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG Response to IV Ketamine in MDD
NCT05506462Phase 4Unknown
- Sponsor
- Ehave
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), sponsored by Ehave. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05506462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506462.